Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | CETP | P11597 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | WNT3A | P56704 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2537570 | 0.82 | GPR119 (0.56) | PTPN2PTPN1PTPN6GPR119USP30 | |
| SCHEMBL2774787 | 0.82 | USP30 (0.60) | PTPN2PTPN1PTPN6GPR119USP30 | |
| SCHEMBL2540012 | 0.79 | GPR119 (0.64) | PTPN2PTPN1PTPN6GPR119CETP | |
| SCHEMBL2538047 | 0.77 | GPR119 (0.53) | GPR119PIK3CD | |
| SCHEMBL14191514 | 0.77 | PTPN2 (0.57) | PTPN2PTPN1PTPN6GPR119USP30 | |
| SCHEMBL19147635 | 0.76 | GPR119 (0.53) | PTPN2PTPN1PTPN6GPR119 | |
| SCHEMBL14191511 | 0.76 | PTPN2 (0.56) | PTPN2PTPN1PTPN6GPR119USP30 | |
| SCHEMBL2774614 | 0.76 | GPR119 (0.59) | GPR119USP30 | |
| SCHEMBL2534569 | 0.76 | GPR119 (0.58) | GPR119 | |
| SCHEMBL2774875 | 0.75 | GPR119 (0.51) | GPR119PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | PTPN2 1638/4885PTPN1 1389/4885PTPN6 1697/4885 |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | HRH3, HRH4, HRH2 | PTPN2 1881/4885PTPN1 1609/4885PTPN6 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.